OBI Pharma (ROCO:4174) Insider Ownership : 0.00 % (As of May. 10, 2025)

View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OBI Pharma's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OBI Pharma's Institutional Ownership is 4.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OBI Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

OBI Pharma Insider Ownership Historical Data

The historical data trend for OBI Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Insider Ownership Chart

OBI Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

Get a 7-Day Free Trial

OBI Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

OBI Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

OBI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011

Website

https://www.obipharma.com

OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines